Remission

Patients with systemic lupus erythematosus who achieve remission, regardless of treatment status, or low disease activity are less likely to accrue as much systematic damage as those who do not reach treatment goals, according to data.

Endoscopic transsphenoidal surgery has the best remission rates and fewest postoperative complications for adults with acromegaly, according to findings from a systematic review.

Children aged 1 to 11 years with eosinophilic esophagitis safely achieved histologic disease remission after 16 weeks of treatment with the fully human monoclonal antibody dupilumab, according to the results of a phase 3 trial.

In youth with Tourette syndrome and other persistent tic disorders, treatment with behavioral therapy was linked with symptom remission and a reduction in tic severity, according to a new study.

For decades, clinicians and researchers have recognized that some people with type 2 diabetes of short duration who adhere to intensive glucose-lowering therapy can achieve normal blood glucose levels and discontinue treatment.

The 2022 EULAR recommendations for the management of rheumatoid arthritis are largely similar to the 2019 updates, with one point of emphasis being the importance of rapid glucocorticoid reduction and discontinuation.

SAN DIEGO — Patients with ulcerative colitis who responded to mirikizumab at 12 weeks achieved and maintained clinical remission and improved bowel urgency severity at 1 year in the phase 3 LUCENT-2 study.

SAN DIEGO — In a Healio video exclusive, Marla C. Dubinsky, MD, discusses results from the ELEVATE UC trials, in which once daily etrasimod induced clinical remission in patients with ulcerative colitis.

A “large proportion” of patients with psoriatic arthritis fail to reach treatment targets despite medication, with residual musculoskeletal and skin disease frequently observed, according to data published in Rheumatology and Therapy.

This month, we are so lucky to have such an extraordinary panel of experts in the field of rheumatoid arthritis — Daniel Aletaha, MD, MSc; Stanley Cohen, MD; Bryant R. England, MD, PhD; Roy Fleischmann, MD; and Liana Fraenkel, MD, MPH — debate the merits of remission vs. low disease activity as the desired target in the therapy of rheumatoid arthritis.